10-K: The Cannaisseur Group Reports 2023 Annual Results, Revenue Declines Amidst Inflationary Pressures

The Cannaisseur Group's 2023 annual report reveals a decrease in revenue and an increase in operating expenses, alongside a net loss, while the company navigates a challenging economic environment.

Summary

• The Cannaisseur Group, Inc. (TCG) reported a revenue of $53,130 for the year ended December 31, 2023, a 39.7% decrease compared to $88,145 in 2022.
• This decline in revenue was attributed to reduced retail sales due to inflation and decreased consumer buying power.
• The cost of revenue also decreased by 37% to $26,976 in 2023, down from $42,839 in 2022, due to lower sales volume.
• Selling, general, and administrative expenses increased by 56.8% to $215,130 in 2023, up from $137,207 in 2022, driven by costs associated with share registration, rent, and salaries.
• The company experienced a net loss of $172,586 for 2023, compared to a net loss of $94,013 in 2022.
• TCG's total assets decreased to $44,617 as of December 31, 2023, from $59,289 in 2022, while total liabilities increased to $136,687 from $81,717.
• The company's cash used in operating activities was $126,074 in 2023, compared to $23,935 in 2022.
• Cash provided by financing activities was $145,930 in 2023, primarily from the sale of common stock and convertible notes.
• The company has a going concern warning due to a net loss, negative cash flow, and a working capital deficit.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant revenue decline, increased expenses, net losses, and a going concern warning. While there are some positives, the overall financial health and future prospects appear challenging.

Positives

• The cost of revenue decreased by 37% due to reduced sales.
• The company secured $145,930 in financing, which included $40,000 from a convertible note.
• The company had a gain on settlement of $18,968 related to a lease termination.

Negatives

• The company experienced a significant decrease in revenue of 39.7% due to reduced retail sales.
• Operating expenses increased by 56.8%, driven by share registration, rent, and salaries.
• The company reported a net loss of $172,586 for the year.
• The company's total assets decreased, while total liabilities increased.
• The company's cash used in operating activities was $126,074.
• The company has a going concern warning due to a net loss, negative cash flow, and a working capital deficit.

Risks

• The company faces risks related to the COVID-19 pandemic, which could disrupt operations and supply chains.
• The company's industry is subject to evolving regulations by the FDA and FTC.
• Increases in the cost of ingredients, labor, and other costs could adversely affect profitability.
• The company does not have long-term contracts with many suppliers, which could lead to price increases or supply issues.
• The company may not be able to adequately protect its intellectual property.
• The company has no outside board of directors, which could create conflicts of interest.
• Cybersecurity risks could lead to data breaches and reputational damage.
• The company has a limited operating history and operates in a new industry.
• The company's financial statements may not be comparable to those of other companies due to the use of extended transition periods for accounting standards.
• The company may not be able to secure additional financing.
• The company's annual and quarterly financial results are subject to significant fluctuations.
• The company may be unable to manage growth effectively.
• The company operates in a highly competitive environment.
• The company does not expect to pay dividends in the future.
• The company's stock is not quoted or traded on any securities market and is subject to penny stock rules.
• The company is dependent on continued market acceptance of its products.
• The company may require additional capital, which may not be available when needed and could be dilutive to existing stockholders.
• The company is an emerging growth company and is subject to reduced disclosure and governance requirements.
• Sales by stockholders of a substantial number of shares could adversely affect the market price of the common stock.

Future Outlook

The company intends to develop its own hemp cultivation, extraction, and manufacturing business and work in conjunction with Atlanta CBD to grow the company's business operations. TCG expects to raise funds through private investors and investment firms and is looking to secure a non-recourse loan for work capital and operating expenses. Long term, the company plans to seek larger amounts of investment to expand its operations.

Management Comments

• Management plans to provide for the Company's capital requirements by continuing to issue additional equity and debt securities.
• Management continues to monitor macro-economic factors such as inflationary pressures, continued Federal Reserve interest rate hikes and recessionary fears, as well as trends within our industry, all of which may affect our working capital requirements.

Industry Context

The report notes that the CBD market is expected to grow significantly, with a predicted compound annual growth rate of 49% by 2024. However, the company faces competition from numerous brands with geocentric distribution footprints and anticipates the entry of major pharmaceutical companies into the market.

Comparison to Industry Standards

• The document does not provide specific comparable companies or projects to benchmark against.
• The company's financial performance, particularly the significant revenue decline and net loss, suggests it is underperforming compared to the broader industry growth projections.
• The lack of profitability and the going concern warning indicate that the company is facing significant challenges compared to industry standards.

Management Changes

Legal Proceedings

• The company was involved in a civil action initiated by its landlord for failing to pay amounts owed under a lease, which was settled through a Lease Termination and Settlement Agreement.

Related Party Transactions

• The company acquired 51% of Atlanta CBD, Inc. from Floretta Gogo and Xavier Carter, who are also officers of the company.
• The company issued 914,286 shares of common stock to a related party for cash proceeds of $20,000.
• The company sold 2,133,332 shares of common stock to two related party investors for cash proceeds of $32,000.
• The company received capital contributions from related parties in the amount of $10,502.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and may not receive dividends.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may experience changes in product availability or pricing due to the company's financial challenges.
• Suppliers may face uncertainty regarding payment and future business with the company.
• Creditors face increased risk due to the company's going concern warning and financial instability.

Next Steps

• The company intends to develop its own hemp cultivation, extraction, and manufacturing business.
• The company plans to raise additional capital through private investors and investment firms.
• The company is looking to secure a non-recourse loan for working capital and operating expenses.
• The company intends to continue offering smaller investment opportunities and plans to seek larger amounts of investment to expand operations.

Key Dates

Keywords

hemp, CBD, cannabinoids, retail, financial results, revenue, net loss, operating expenses, convertible note, going concern, regulation, risk factors